AU2002313700B2 - Method for reducing hypertension and heart failure - Google Patents

Method for reducing hypertension and heart failure Download PDF

Info

Publication number
AU2002313700B2
AU2002313700B2 AU2002313700A AU2002313700A AU2002313700B2 AU 2002313700 B2 AU2002313700 B2 AU 2002313700B2 AU 2002313700 A AU2002313700 A AU 2002313700A AU 2002313700 A AU2002313700 A AU 2002313700A AU 2002313700 B2 AU2002313700 B2 AU 2002313700B2
Authority
AU
Australia
Prior art keywords
heart
tyrphostin
set forth
hypertrophy
hypertension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002313700A
Other languages
English (en)
Other versions
AU2002313700A1 (en
Inventor
Daniel L Beckles
Eduardo Mascareno
M A Q Siddiqui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of the State University of New York
Original Assignee
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation of the State University of New York filed Critical Research Foundation of the State University of New York
Publication of AU2002313700A1 publication Critical patent/AU2002313700A1/en
Application granted granted Critical
Publication of AU2002313700B2 publication Critical patent/AU2002313700B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2002313700A 2001-08-31 2002-07-23 Method for reducing hypertension and heart failure Ceased AU2002313700B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/945,192 US6433018B1 (en) 2001-08-31 2001-08-31 Method for reducing hypertrophy and ischemia
US09/945,192 2001-08-31
PCT/US2002/023444 WO2003020202A2 (en) 2001-08-31 2002-07-23 Method for reducing hypertension and heart failure

Publications (2)

Publication Number Publication Date
AU2002313700A1 AU2002313700A1 (en) 2003-06-05
AU2002313700B2 true AU2002313700B2 (en) 2007-04-26

Family

ID=25482762

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002313700A Ceased AU2002313700B2 (en) 2001-08-31 2002-07-23 Method for reducing hypertension and heart failure

Country Status (11)

Country Link
US (2) US6433018B1 (https=)
EP (1) EP1427401A4 (https=)
JP (2) JP2005505545A (https=)
KR (1) KR20040050894A (https=)
AU (1) AU2002313700B2 (https=)
BR (1) BR0212252A (https=)
CA (1) CA2458798C (https=)
MX (1) MXPA04001913A (https=)
NZ (1) NZ531693A (https=)
WO (1) WO2003020202A2 (https=)
ZA (1) ZA200402540B (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6433018B1 (en) * 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US20050038450A1 (en) * 2003-06-03 2005-02-17 Ping Hu Methods and apparatus for minimally invasive transverse aortic banding
WO2005012294A1 (en) * 2003-07-30 2005-02-10 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
US20050130893A1 (en) * 2003-09-30 2005-06-16 Joan Smith-Sonneborn Use of opioids in prevention of and recovery from a stress-induced crash in blood pressure
MXPA06006460A (es) 2003-12-11 2006-08-23 Univ Texas Compuestos para el tratamiento de enfermedades proliferativas celulares.
TWI398261B (zh) * 2003-12-17 2013-06-11 Alcon Inc 血清類澱粉ａ基因於診斷及治療青光眼及鑑定抗青光眼劑上之用途
US7662389B2 (en) * 2003-12-17 2010-02-16 Alcon, Inc. Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
US20100113481A1 (en) * 2003-12-17 2010-05-06 Alcon Research, Ltd. Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
WO2006044694A2 (en) * 2004-10-15 2006-04-27 Palo Alto Investors Methods and compositions for treating a disease condition in a subject
US20070203161A1 (en) * 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
BRPI0610876B8 (pt) 2005-06-08 2021-05-25 Rigel Pharmaceuticals Inc composto, formulação farmacêutica, e métodos de inibir uma atividade de uma jak cinase, e de inibir uma cascata de transdução de sinal em que jak3 cinase desempenha um papel
WO2007058627A1 (en) 2005-11-16 2007-05-24 S*Bio Pte Ltd Oxygen linked pyrimidine derivatives
US10517876B2 (en) 2005-11-16 2019-12-31 Cti Biopharma Corp. Oxygen linked pyrimidine derivatives
EP1983848A2 (en) * 2006-01-13 2008-10-29 The President and Fellows of Harvard College Xenohormesis based compositions and methods
ES2622493T3 (es) * 2006-02-24 2017-07-06 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta de JAK
BRPI0708347A2 (pt) * 2006-02-28 2011-05-24 Cytopia Res Pty Ltd inibição jak2 como um tratamento da hipertensão arterial pulmonar
RU2456265C2 (ru) * 2006-03-31 2012-07-20 Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем Биологически доступная для перорального применения кофейная кислота, относящаяся к противоопухолевым лекарственным средствам
KR101566840B1 (ko) 2007-03-12 2015-11-06 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 페닐 아미노 피리미딘 화합물 및 이의 용도
HUE030912T2 (en) 2008-02-15 2017-06-28 Rigel Pharmaceuticals Inc Pyrimidine-2-amine compounds and their use as inhibitors of yak kinases
US8063058B2 (en) 2008-04-16 2011-11-22 Portola Pharmaceuticals, Inc. Inhibitors of syk and JAK protein kinases
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
AU2009238590A1 (en) * 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US10517839B2 (en) * 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
AU2009268841B2 (en) 2008-07-08 2014-02-06 Board Of Regents, The University Of Texas System Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (STATS)
PL2376499T3 (pl) 2008-12-11 2015-07-31 Cti Biopharma Corp Sól cytrynianowa 11-(2-pirrolidyn-1-yloetoksy)-14,19-dioksa-5,7,26-triazatetracyklo[19.3.1.1(2,6).1(8,12)]heptakosa-1(25),2(26),3,5,8,10,12(27),16,21,23-dekaenu
CN106420756A (zh) * 2009-07-28 2017-02-22 里格尔药品股份有限公司 抑制jak途径的组合物和方法
JP5275966B2 (ja) * 2009-12-21 2013-08-28 パナソニック株式会社 繊維ボードの製造方法
EP2975027A1 (en) 2010-11-01 2016-01-20 Portola Pharmaceuticals, Inc. Nicotinamides as jak kinase modulators
MX363551B (es) 2011-11-23 2019-03-27 Portola Pharmaceuticals Inc Star Compuestos derivados de pirazina como inhibidores de cinasa.
US8809359B2 (en) 2012-06-29 2014-08-19 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine bicyclic compounds and uses thereof
WO2014058921A2 (en) 2012-10-08 2014-04-17 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
TWI729644B (zh) 2014-06-12 2021-06-01 美商西爾拉癌症醫學公司 N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
CA2012634A1 (en) * 1990-03-20 1991-09-20 Hassan Salari Tyrphostins for treatment of allergic, inflammatory and cardiovascular diseases
US5443836A (en) 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
US6255296B1 (en) 1994-01-11 2001-07-03 Endomatrix, Inc. Composition and method for treating a patient susceptible to or suffering from a cardiovascular disorder or disease
IL119069A0 (en) 1996-08-14 1996-11-14 Mor Research Applic Ltd Pharmaceutical composition comprising tyrphostins
US6358954B1 (en) 1999-11-09 2002-03-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same
US6433018B1 (en) * 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
DE602006000402T8 (de) * 2006-06-02 2009-04-09 Teva Pharmaceutical Industries Ltd. Stabile Zubereitung enthaltend eine feuchtigkeitsempfindliche aktive Substanz und Verfahren zur Herstellung der Zubereitung.

Also Published As

Publication number Publication date
WO2003020202A2 (en) 2003-03-13
CA2458798C (en) 2013-06-25
JP2010285455A (ja) 2010-12-24
NZ531693A (en) 2006-05-26
US20040266661A1 (en) 2004-12-30
MXPA04001913A (es) 2004-06-18
EP1427401A2 (en) 2004-06-16
JP2005505545A (ja) 2005-02-24
WO2003020202A3 (en) 2003-08-28
ZA200402540B (en) 2005-06-29
EP1427401A4 (en) 2009-04-29
US6433018B1 (en) 2002-08-13
CA2458798A1 (en) 2003-03-13
KR20040050894A (ko) 2004-06-17
US7235588B2 (en) 2007-06-26
BR0212252A (pt) 2004-09-14

Similar Documents

Publication Publication Date Title
AU2002313700B2 (en) Method for reducing hypertension and heart failure
AU2002313700A1 (en) Method for reducing hypertension and heart failure
JP2010001311A (ja) 心肥大のための処置としてのヒストンデアセチラーゼの阻害
Lawrie et al. Paigen diet–fed apolipoprotein E knockout mice develop severe pulmonary hypertension in an interleukin-1–dependent manner
WO2017147532A1 (en) Alpha-1-adrenergic receptor agonist therapy
KR20010031177A (ko) 레닌-안지오텐신 시스템 억제제의 용도
JP7193874B2 (ja) 筋肉Ａキナーゼアンカータンパク質（ｍＡＫＡＰ）作用の阻害による心臓病の処置
Shi et al. The histone deacetylase inhibitor SAHA exerts a protective effect against myocardial ischemia/reperfusion injury by inhibiting sodium-calcium exchanger
Ren et al. Salidroside treatment decreases the susceptibility of atrial fibrillation in diabetic mice by reducing mTOR-STAT3-MCP-1 signaling and atrial inflammation
JP7613693B2 (ja) Ｐｐ２ａアンカリングの阻害による心疾患の処置
US20070219180A1 (en) Muscle Relaxtion Accelerator and Therapeutic Agent for Muscular Tissue Diseases Such as Muscle Relaxation Failure
WO2021073249A1 (zh) β-NMN在制备脓毒症器官损伤的治疗、预防药物中的应用
CN103429242A (zh) 用于预防和治疗心脏肥大的方法和组合物
CN113271949A (zh) 用于治疗骨关节炎的西地那非
US20120288486A1 (en) Method for Ameliorating or Preventing Arrhythmic Risk Associated with Cardiomyopathy
EP3756667B1 (en) Inhibitors of adamts4 or adamts5 for use in preventing or treating cardiac remodeling and chronic heart failure
WO2020023922A9 (en) Biomarker for thoracic aortic aneurysm
US20170027926A1 (en) Compositions and methods of inhibiting histone deacetylases
TW202529758A (zh) 用於治療疾病及病症之ｈｄａｃ６選擇性抑制劑
JP2003531114A (ja) プロテインキナーゼα阻害剤の使用
WO2026080202A1 (en) Methods and materials for treating chronic heart disorders
Karsentya et al. SESSION PL ENIERE: METABOLISMES, DU GENE AU PATIENT
WO2014070706A1 (en) Control of cardiac growth, differentiation and hypertrophy
LaRocca et al. The Na/Ca 2 exchanger-1 protects against 3 systolic failure in the Akita ins2 model of diabetic 4 cardiomyopathy via a CXCR4/NF-κB pathway 5
Kugathasan The Protective Role of the Angiopoetin-1-Tie2 System in Transgenic Models of Pulmonary Arterial Hypertension

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: ADD THE CO-INVENTOR BECKLES, DANIEL L

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired